# Validate Gene Expression and Proteomic Signatures Predictive of Treatment for Response for Breast Cancer Patient

> **NCT00669773** · PHASE2 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 49 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Adriamycin
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00669773
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-02
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2013-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00669773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00669773, "Validate Gene Expression and Proteomic Signatures Predictive of Treatment for Response for Breast Cancer Patient". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00669773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*